Tobira Therapeutics Inc. (NASDAQ:TBRA) traded up 5.1% during trading on Thursday . The stock traded as high as $4.38 and last traded at $4.35, with a volume of 264,056 shares trading hands. The stock had previously closed at $4.14.

Several equities research analysts recently commented on the company. HC Wainwright restated a “buy” rating on shares of Tobira Therapeutics in a research report on Wednesday, May 4th. Leerink Swann restated a “buy” rating on shares of Tobira Therapeutics in a research report on Monday, May 2nd. Zacks Investment Research lowered Tobira Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday. Finally, Cantor Fitzgerald lowered Tobira Therapeutics to a “buy” rating and set a $19.00 target price on the stock. in a research report on Monday. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $18.60.

The stock’s market cap is $80.34 million. The stock has a 50-day moving average of $11.18 and a 200 day moving average of $8.68.

Tobira Therapeutics (NASDAQ:TBRA) last issued its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by $0.12. Equities research analysts expect that Tobira Therapeutics Inc. will post ($2.49) EPS for the current year.

In other Tobira Therapeutics news, major shareholder A/S Novo sold 66,814 shares of Tobira Therapeutics stock in a transaction dated Thursday, June 30th. The stock was sold at an average price of $13.04, for a total transaction of $871,254.56. Following the completion of the sale, the insider now owns 2,073,022 shares of the company’s stock, valued at $27,032,206.88. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

A hedge fund recently bought a new stake in Tobira Therapeutics stock. Marshall Wace LLP acquired a new stake in Tobira Therapeutics Inc. (NASDAQ:TBRA) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 107,493 shares of the biopharmaceutical company’s stock, valued at approximately $1,080,000. Marshall Wace LLP owned approximately 0.57% of Tobira Therapeutics at the end of the most recent quarter.

Tobira Therapeutics, Inc, formerly Regado Biosciences, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.